4-异丁基哌嗪-1-甲醛 | 21863-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-异丁基哌嗪-1-甲醛
• 英文名称: N-Isobutyl-N'-formyl-piperazin
• 英文别名: 1-formyl-4-isobutyl-piperazine；4-(2-Methylpropyl)piperazine-1-carbaldehyde
• CAS: 21863-68-3
• 化学式: C₉H₁₈N₂O
• 分子量: 170.255
• InChiKey: AXXHITGPZZKPSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

文献信息

• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：EP1820799A1

  公开（公告）日：2007-08-22

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明的目的是提供一种用化学式（1）表示的2,3,4,5-四氢-1H-1,5-苯二氮䓬衍生物，或其药学上可接受的盐，作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药剂。
• Substituted indole ligands for the ORL-1 receptor
  申请人：Ronzoni Silvano

  公开号：US20090275555A1

  公开（公告）日：2009-11-05

  New ligands for the ORL-1 receptor are described, useful for antagonising the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the activation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further defined in the description.

  本文描述了ORL-1受体的新配体，可用于拮抗需要该受体活性的患者，并用于预防和治疗依赖于该受体激活的疾病。新化合物符合结构式（I），其中R1，R2，R3，R4在描述中进一步定义。
• Inhibitors of C-FMS Kinase
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP2687516A1

  公开（公告）日：2014-01-22

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式 I 的化合物： 其中Z、X、J、R2和W如说明书所述，以及它们的溶解物、水合物、同系物和药学上可接受的盐，可抑制蛋白酪氨酸激酶，特别是c-fms激酶。治疗自身免疫性疾病的方法；治疗具有炎症成分的疾病的方法；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小肺癌转移的方法；治疗疼痛的方法，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏疼痛、炎症疼痛和神经源性疼痛；以及骨质疏松症、Paget 病和其他骨吸收介导发病的疾病，包括关节炎、假体失效、溶骨性肉瘤、骨髓瘤和肿瘤向骨骼转移，也提供了式 I 化合物。
• INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1663999A2

  公开（公告）日：2006-06-07
• US7468371B2
  申请人：——

  公开号：US7468371B2

  公开（公告）日：2008-12-23